AR129238A1 - Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras - Google Patents
Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nrasInfo
- Publication number
- AR129238A1 AR129238A1 ARP230101103A ARP230101103A AR129238A1 AR 129238 A1 AR129238 A1 AR 129238A1 AR P230101103 A ARP230101103 A AR P230101103A AR P230101103 A ARP230101103 A AR P230101103A AR 129238 A1 AR129238 A1 AR 129238A1
- Authority
- AR
- Argentina
- Prior art keywords
- cyclic compound
- kras
- hras
- nras
- inhibitory action
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un compuesto cíclico representado por la fórmula (1). Un compuesto cíclico o una sal o un solvato de este, caracterizado porque el compuesto se selecciona del grupo que consiste en PP1574, PP1650, PP1827, PP1830, PP2093, PP2260, PP2316, PP2320, PP2328, PP2574 PP2576, PP2583, PP2687, PP2691, PP2957, PP3033, PP3034, PP3036, PP3037, PP3047, PP3093, PP3094, PP3095, PP3096, PP3097, PP3098, PP3099, PP3100, PP3101, PP3102, PP3103, PP3104, PP3105, PP3106, PP3110, PP3111, PP3112, PP3113, PP3114, PP3115, PP3116, PP3117, PP3118, PP3119, PP3120 y PP3121. Un solvato del compuesto cíclico o una sal de este según la reivindicación 4. Una composición farmacéutica caracterizada porque comprende el compuesto cíclico o una sal o solvato de este según una cualquiera de las reivindicaciones 1 a 8. Una composición farmacéutica para inhibir selectivamente KRAS en un sujeto, la composición caracterizada porque comprende el compuesto cíclico o una sal o solvato de este según una cualquiera de las reivindicaciones 1 a 8. Una composición farmacéutica para tratar o prevenir el cáncer en un sujeto, la composición caracterizada porque comprende una cantidad eficaz del compuesto cíclico o una sal o solvato de este según una cualquiera de las reivindicaciones 1 a 8.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022076449 | 2022-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129238A1 true AR129238A1 (es) | 2024-07-31 |
Family
ID=88646541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101103A AR129238A1 (es) | 2022-05-06 | 2023-05-05 | Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12410212B2 (es) |
| EP (1) | EP4512818A1 (es) |
| JP (1) | JPWO2023214576A1 (es) |
| KR (1) | KR20250008758A (es) |
| CN (1) | CN119731195A (es) |
| AR (1) | AR129238A1 (es) |
| AU (1) | AU2023264918A1 (es) |
| CA (1) | CA3256645A1 (es) |
| CL (1) | CL2024003354A1 (es) |
| CO (1) | CO2024016293A2 (es) |
| IL (1) | IL316253A (es) |
| MX (1) | MX2024013352A (es) |
| PE (1) | PE20251872A1 (es) |
| TW (1) | TW202406927A (es) |
| WO (1) | WO2023214576A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI579296B (zh) | 2011-12-28 | 2017-04-21 | Chugai Pharmaceutical Co Ltd | Cyclization of Peptide Compounds |
| US12391971B2 (en) | 2017-01-31 | 2025-08-19 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptides in cell-free translation system |
| US11542299B2 (en) | 2017-06-09 | 2023-01-03 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptide containing N-substituted amino acid |
| JP7279073B2 (ja) | 2018-11-07 | 2023-05-22 | 中外製薬株式会社 | Ｏ－置換セリン誘導体の製造方法 |
| TWI850887B (zh) | 2019-11-07 | 2024-08-01 | 日商中外製藥股份有限公司 | 具有Kras抑制作用的環狀胜肽化合物 |
| JP7625531B2 (ja) | 2019-11-07 | 2025-02-03 | 中外製薬株式会社 | 立体障害の大きなアミノ酸を含むペプチド化合物の製造方法 |
| TW202309065A (zh) | 2021-05-07 | 2023-03-01 | 日商中外製藥股份有限公司 | 包含n-取代胺基酸殘基之環狀化合物的製造方法 |
| WO2024101386A1 (ja) * | 2022-11-09 | 2024-05-16 | 中外製薬株式会社 | Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物 |
| WO2024101402A1 (ja) * | 2022-11-09 | 2024-05-16 | 中外製薬株式会社 | Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物を含む医薬組成物 |
| CN120731215A (zh) | 2023-03-20 | 2025-09-30 | 中外制药株式会社 | 用于产生环肽的共晶的方法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025162428A1 (en) * | 2024-01-29 | 2025-08-07 | Syneron Technology Co. Ltd. | Cyclic peptide compounds and compositions as ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025192626A1 (ja) * | 2024-03-13 | 2025-09-18 | 中外製薬株式会社 | 環構造を有するペプチド化合物の製造方法 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026004834A1 (ja) * | 2024-06-25 | 2026-01-02 | 中外製薬株式会社 | 固体分散体、及びそれを含む組成物 |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122059A1 (en) | 2011-03-04 | 2012-09-13 | New York University | Hydrogen bond surrogate macrocycles as modulators of ras |
| WO2012171984A1 (en) | 2011-06-16 | 2012-12-20 | Lonza Ltd | A process for extraction of peptides and its application in liquid phase peptide synthesis |
| TWI579296B (zh) | 2011-12-28 | 2017-04-21 | Chugai Pharmaceutical Co Ltd | Cyclization of Peptide Compounds |
| HK1249052A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗与ras突变相关的癌症的方法 |
| DK3269809T3 (da) | 2015-03-13 | 2022-09-12 | Chugai Pharmaceutical Co Ltd | MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF |
| MX382355B (es) | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| EP3424941A4 (en) | 2016-03-03 | 2019-10-23 | Chugai Seiyaku Kabushiki Kaisha | PROCESS FOR THE PRODUCTION OF NON-CYCLIC PEPTIDE-NUCLEIC ACID COMPLEX HAVING AT AN N-TERMINAL END AN AMINO ACID HAVING A THIOL GROUP NEAR THE AMINO GROUP, A CORRESPONDING LIBRARY, AND A LIBRARY OF THE PEPTIDE-CYCLIC NUCLEIC ACID COMPOUND THUS DERIVED |
| EP3442991A4 (en) | 2016-04-15 | 2019-11-20 | RA Pharmaceuticals, Inc. | RAS-BINDING PEPTIDES AND METHODS OF USE |
| WO2018124162A1 (ja) | 2016-12-28 | 2018-07-05 | 中外製薬株式会社 | 化合物の膜透過性を改善するための自己乳化型製剤 |
| US12391971B2 (en) | 2017-01-31 | 2025-08-19 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptides in cell-free translation system |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US11542299B2 (en) | 2017-06-09 | 2023-01-03 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptide containing N-substituted amino acid |
| JP7232758B2 (ja) | 2017-06-09 | 2023-03-06 | 中外製薬株式会社 | 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ |
| IL274601B2 (en) | 2017-11-15 | 2024-04-01 | Mirati Therapeutics Inc | Kras g12c inhibitors |
| US11492369B2 (en) | 2017-12-15 | 2022-11-08 | Chugai Seiyaku Kabushiki Kaisha | Method for producing peptide, and method for processing bases |
| GB201805088D0 (en) | 2018-03-28 | 2018-05-09 | Univ Warwick | Macrocyclization of peptidomimetics |
| JP7279073B2 (ja) | 2018-11-07 | 2023-05-22 | 中外製薬株式会社 | Ｏ－置換セリン誘導体の製造方法 |
| CN119143631A (zh) | 2018-11-30 | 2024-12-17 | 中外制药株式会社 | 用于肽化合物或酰胺化合物的脱保护方法和在固相反应中的树脂脱除方法以及用于生产肽化合物的方法 |
| JP7531401B2 (ja) | 2018-12-12 | 2024-08-09 | 中外製薬株式会社 | 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法 |
| CN113423877B (zh) | 2018-12-26 | 2024-09-13 | 中外制药株式会社 | 用于密码子扩展的突变tRNA |
| JP7472101B2 (ja) | 2019-03-15 | 2024-04-22 | 中外製薬株式会社 | 芳香族アミノ酸誘導体の製造方法 |
| TWI850887B (zh) | 2019-11-07 | 2024-08-01 | 日商中外製藥股份有限公司 | 具有Kras抑制作用的環狀胜肽化合物 |
| JP7625531B2 (ja) | 2019-11-07 | 2025-02-03 | 中外製薬株式会社 | 立体障害の大きなアミノ酸を含むペプチド化合物の製造方法 |
| US20230108274A1 (en) | 2019-12-26 | 2023-04-06 | Chugai Seiyaku Kabushiki Kaisha | Composition for translation, and method for producing peptide |
| KR20220119421A (ko) | 2019-12-27 | 2022-08-29 | 추가이 세이야쿠 가부시키가이샤 | 펩타이드 화합물의 합성법 |
| US20230295221A1 (en) | 2020-06-03 | 2023-09-21 | Chugai Seiyaku Kabushiki Kaisha | Efficient peptide condensation method for difficult sequences |
| KR20230028363A (ko) | 2020-06-25 | 2023-02-28 | 추가이 세이야쿠 가부시키가이샤 | 개변된 유전 암호표를 갖는 번역계 |
| JP7808554B2 (ja) | 2020-11-05 | 2026-01-29 | 中外製薬株式会社 | ジケトピペラジン形成による欠損を抑制するペプチド合成方法 |
| JPWO2022138891A1 (es) | 2020-12-25 | 2022-06-30 | ||
| TW202241921A (zh) | 2020-12-28 | 2022-11-01 | 日商中外製藥股份有限公司 | 將胺基酸負載至固相合成用樹脂的方法 |
| CN117241817A (zh) | 2021-05-07 | 2023-12-15 | 中外制药株式会社 | 包含环状肽化合物的制剂及其制备方法 |
| TW202309065A (zh) | 2021-05-07 | 2023-03-01 | 日商中外製藥股份有限公司 | 包含n-取代胺基酸殘基之環狀化合物的製造方法 |
| CN117279655A (zh) | 2021-05-07 | 2023-12-22 | 中外制药株式会社 | 环状肽化合物的药物用途 |
| WO2022234639A1 (ja) | 2021-05-07 | 2022-11-10 | 中外製薬株式会社 | 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子 |
| AR125796A1 (es) * | 2021-05-07 | 2023-08-16 | Chugai Pharmaceutical Co Ltd | Compuesto cíclico que tiene una acción inhibitoria selectiva en kras sobre hras y nras |
| KR102844018B1 (ko) | 2021-12-28 | 2025-08-07 | 추가이 세이야쿠 가부시키가이샤 | N-알킬 아미노산, 및 n-알킬 아미노산을 포함하는 펩타이드의 제조 방법 |
| IL313434A (en) | 2022-01-21 | 2024-08-01 | Chugai Pharmaceutical Co Ltd | Medicine for treating or preventing cancer |
| KR20250006193A (ko) | 2022-05-02 | 2025-01-10 | 추가이 세이야쿠 가부시키가이샤 | 디케토피페라진 형성에 의한 결손을 억제하는 펩티드 합성 방법 |
-
2023
- 2023-05-02 AU AU2023264918A patent/AU2023264918A1/en active Pending
- 2023-05-02 KR KR1020247039424A patent/KR20250008758A/ko active Pending
- 2023-05-02 WO PCT/JP2023/017112 patent/WO2023214576A1/ja not_active Ceased
- 2023-05-02 TW TW112116268A patent/TW202406927A/zh unknown
- 2023-05-02 PE PE2024002242A patent/PE20251872A1/es unknown
- 2023-05-02 EP EP23799505.5A patent/EP4512818A1/en active Pending
- 2023-05-02 JP JP2024519229A patent/JPWO2023214576A1/ja active Pending
- 2023-05-02 CA CA3256645A patent/CA3256645A1/en active Pending
- 2023-05-02 CN CN202380038438.6A patent/CN119731195A/zh active Pending
- 2023-05-02 IL IL316253A patent/IL316253A/en unknown
- 2023-05-05 AR ARP230101103A patent/AR129238A1/es unknown
-
2024
- 2024-09-10 US US18/829,566 patent/US12410212B2/en active Active
- 2024-10-29 MX MX2024013352A patent/MX2024013352A/es unknown
- 2024-11-04 CL CL2024003354A patent/CL2024003354A1/es unknown
- 2024-11-28 CO CONC2024/0016293A patent/CO2024016293A2/es unknown
-
2025
- 2025-02-18 US US19/055,932 patent/US20250230193A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024003354A1 (es) | 2025-03-21 |
| TW202406927A (zh) | 2024-02-16 |
| CO2024016293A2 (es) | 2025-02-24 |
| US20250051394A1 (en) | 2025-02-13 |
| PE20251872A1 (es) | 2025-07-22 |
| JPWO2023214576A1 (es) | 2023-11-09 |
| US20250230193A1 (en) | 2025-07-17 |
| WO2023214576A1 (ja) | 2023-11-09 |
| CA3256645A1 (en) | 2025-04-23 |
| EP4512818A1 (en) | 2025-02-26 |
| MX2024013352A (es) | 2024-12-06 |
| CN119731195A (zh) | 2025-03-28 |
| IL316253A (en) | 2025-01-01 |
| US12410212B2 (en) | 2025-09-09 |
| KR20250008758A (ko) | 2025-01-15 |
| AU2023264918A1 (en) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129238A1 (es) | Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras | |
| AR120700A1 (es) | Inhibidores de kras g12c | |
| CL2021002965A1 (es) | Compuestos antivirales que contienen nitrilo. | |
| MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2023001689A (es) | Inhibidores de bcl-2. | |
| AR112271A1 (es) | Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales | |
| AR126251A1 (es) | Inhibidores de cdk2 | |
| CR20190257A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| AR114738A1 (es) | Moduladores de la expresión de pnpla3 | |
| AR123284A1 (es) | Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9 | |
| AR123285A1 (es) | Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9 | |
| DOP2025000044A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| CO2025016753A2 (es) | Inhibidores de gsk3α y métodos de uso de estos | |
| AR123281A1 (es) | Compuestos bicíclicos sustituidos útiles como inhibidores de tlr9 | |
| MX2025013861A (es) | Compuestos anti virus de la inmunodeficiencia humana (vih) | |
| MX2019004842A (es) | Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. | |
| CL2022002641A1 (es) | Agente para el tratamiento de lesión renal aguda inducida por medio de contraste | |
| AR128106A1 (es) | Tetrahidrobenzoazepinonas y análogos relacionados para la inhibición de yap / taz-tead | |
| CO2025012293A2 (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| AR133935A1 (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| AR132408A1 (es) | Compuestos que modulan kras | |
| AR133133A1 (es) | Compuestos que modulan kras | |
| AR133957A1 (es) | Inhibidores de kat6 | |
| CO2024009030A2 (es) | Composición farmacéutica para prevenir o tratar cáncer de mama triple negativo |